Since further recent articles came to the same conclusion for glioma (7–9) as for hepatocellular cancer (HCC) (10, 11), targeting of CD133 remains an attractive therapeutic concept for these cancer entities and possibly also for others. This evidence concerns the gene PROM1 and cancer.